Navigation Links
Insulet Appoints Peter J. Devlin as Chief Commercial Officer
Date:8/17/2009

BEDFORD, Mass., Aug. 17 /PRNewswire-FirstCall/ --Insulet Corporation (Nasdaq: PODD), the leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management System, today announced the appointment of Peter J. Devlin as Chief Commercial Officer. In this newly created role, Mr. Devlin will lead the Company's Sales and Marketing, Business Development, Clinical Research and Customer Care operations.

"Peter brings a distinguished track record in the diabetes and medical device industries and we are extremely pleased to have him join Insulet's management team," said Duane DeSisto, president & chief executive officer of Insulet. "Peter's proven ability to develop and implement successful commercial strategies globally will be invaluable to Insulet as we continue to grow our core insulin pump business and expand into new opportunities for the easy-to-use OmniPod System."

Mr. Devlin spent the last 11 years at Abbott Laboratories, most recently serving as Divisional Vice President of Global Strategic Marketing, Diabetes Care. In this role, he was responsible for the development of commercial strategies, global brand management, market research, area strategic marketing, and business analytics and forecasting. Previously, Mr. Devlin served as Marketing Manager of i-STAT Corporation, a point-of-care blood analysis systems company, which was acquired by Abbott. Prior, Mr. Devlin spent eight years at C.R. Bard Inc., where he held various product management and engineering roles of increasing responsibility. Mr. Devlin holds a Bachelor of Science degree in Mechanical Engineering from the University of Massachusetts.

"I am eager to join Insulet at this exciting time as the OmniPod System transitions from being a new technology to the standard of care in the insulin pump market," said Mr. Devlin. "I am also excited to help Insulet realize the promise of its innovative delivery system in a broad range of therapies."

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

    Contact:
    Stephanie Marks for Insulet Corporation
    ir@insulet.com
    877-PODD-IR1 (877-763-3471)


'/>"/>
SOURCE Insulet Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Insulet Corporation to Present at Upcoming Investor Conferences
2. Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday, August 4, 2009
3. Insulet Establishes Eco-Friendly Disposal Program for the OmniPod(R) Insulin Management System
4. Insulet Applauds Employee for Bronze Medal Performance in World Blind Sailing Championships
5. Insulet Receives CE Mark for the OmniPod(R) Insulin Management System
6. Insulet Corporation to Report First Quarter 2009 Financial Results on Thursday, May 7, 2009
7. Insulet Receives $60 Million Funding Commitment
8. Insulet Reports Fourth Quarter and Year End 2008 Results
9. Insulet Corporation to Report Fourth Quarter and Full Year 2008 Financial Results on Thursday, March 5, 2009
10. Insulet Corporation to Present at the J.P. Morgan Healthcare Conference on January 14, 2009
11. Insulet Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... The ... today, as organizations, advocates, and individuals join together to increase recognition about the ... ultimately save lives. , “Today we mark a nationwide movement to raise awareness ...
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a ... derive a heart-protective benefit from eating soy foods, while others do not, a University ... are able to produce equol—a substance made by some types of “good” gut bacteria ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Pet obesity ... and 54% of dogs, according to the Association for Pet Obesity Prevention (APOP). During ... key pet food issues such as the benefits of corn and grains, value of ...
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/21/2017)... , ... February 21, 2017 , ... ... Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , The celebration ... tours for community members, clinic employees, the construction team and tribal leadership. ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Feb 22, 2017 Research and ... Market Analysis & Trends - Industry Forecast to 2025" report to ... The Global ... around 5.2% over the next decade to reach approximately $2.1 billion by ... and forecasts for all the given segments on global as well as ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Applied Silver, the ... Barnes to the company,s advisory board. Ms. Barnes is ... joining business, advertising, engineering, legal, and healthcare experts Scott ... John Goodrich , J. Tress Ritter , and ... BSN, CIC, FAPIC brings more than three decades of nationally ...
(Date:2/22/2017)... 2017 Oncternal Therapeutics, Inc., a clinical-stage ... and common malignancies, today announced the closing of ... intends to use the proceeds to further clinical ... advance preclinical development of a new ROR1-targeted antibody-drug ... first-in-class anti-ROR1 monoclonal antibody being developed to treat ...
Breaking Medicine Technology: